New PET tracer could reveal if immunotherapy is working in real time
NCT ID NCT05629689
First seen Nov 17, 2025 · Last updated Jun 11, 2026 · Updated 27 times
Summary
This early-phase study tests a new imaging agent (GEH200520/GEH200521) in 50 adults with advanced solid tumors. Part A checks safety and how the agent behaves in the body. Part B uses PET scans before and after immunotherapy to see if the agent can show changes in tumors. The goal is to improve how doctors monitor treatment response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ONCOLOGY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Amsterdam UMC
NOT_YET_RECRUITINGAmsterdam, Netherlands
-
UMC Groningen
RECRUITINGGroningen, Netherlands
Contact
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.